Economy
-
-
USD/SGD trade outlook: MAS tightening points to further SGD gains
-
Figma stock analysis: IPO hangover, strong fundamentals, and a contested valuation
-
U.S. approves possible $24.3 billion F-35 sale to Saudi Arabia
-
FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
-
Oramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting
-
A critical pipeline that helped cushion the Hormuz shock just shut: Here’s what it reveals about corporate energy security
Saudi Arabia’s East-West pipeline was closed this week after serving as one of the largest buffers against this year’s historic Strait of Hormuz energy shock. Together with the UAE’s bypass pipeline, the two routes carried approximately 5 million additional barrels a day around the Strait in the second quarter, compared to their fourth quarter 2025…
-
The people building the most powerful AI are telling us to slow down. Congress should listen before it’s too late
Something remarkable happened inside the artificial intelligence industry last week. A researcher who spent three years at OpenAI and Anthropic, resigned from Anthropic while warning that the companies developing the world’s most powerful AI systems are moving too quickly toward increasingly capable systems without adequate safeguards. Days later, Anthropic CEO Dario Amodei called on the…
-
Trump just explained why an AI agency cannot work. He is right
On Monday the President posted that the only guardrail artificial intelligence needs is “a STRONG AND SMART (High IQ!) PRESIDENT.” The reflex in Washington and in the labs is to treat this as an obstacle. It is better understood as a warning. Since the Supreme Court decided Trump v. Slaughter in June, every federal agency…
-
Former White House economist: science has delivered a cancer detection revolution, now the FDA must keep pace
Cancer is the leading cause of death among Americans ages 45 to 64. Two major reasons why are that we find most cancers too late and our cancer-screening system remains remarkably narrow. Start with the status quo, which nobody should defend. Routine screening exists for only a handful of cancers. Together, recommended screening programs catch only about one…